Linked Life Data

10432067

Source:http://linkedlifedata.com/resource/pubmed/id/10432067

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-8-17
pubmed:abstractText
The efficacy and tolerability of single, low-dose mefloquine, sulfadoxine-pyrimethamine (MSP) combination was compared with chloroquine (CQ) for malaria treatment in a malaria-endemic area of Nigeria with multiple drug-resistant Plasmodium falciparum. The two drug regimens (MSP and CQ) were tested in a 12-month prospective population study. The patients were divided into two groups. Group 1 patients were treated presumptively, based on malaria symptoms. Group 2 patients were treated based on a parasitologic diagnosis using the World Health Organization seven-day in vivo test and extended to a 28-day follow-up period. Tolerability was assessed by the incidence and intensity of adverse events. One thousand nine hundred thirty-five patients visiting 10 health facilities, including the University of Calabar Teaching Hospital, were enrolled. The study showed that the low-dose MSP was efficacious, with day 7 response rates of 95% and 91% for (presumptive) Group 1 and (in vivo) Group 2, respectively, while CQ had day 7 response rates of 82% and 66% in Groups 1 and 2, respectively. The low-dose MSP was significantly (P < 0.0001) more efficacious, with faster fever and parasite clearance times than CQ in this area of CQ-resistant P. falciparum malaria. Eight patients treated with CQ, including seven severe cases (RII-RIII) were successfully re-treated with MSP. Adverse events were generally more common among those treated with MSP (29%) than those treated with CQ (17%). However, the adverse events caused by both drugs were mild to moderate and self-limited. The MSP combination appears to be a good substitute for CQ, in view of multiple drug resistance, especially in areas with severe (RII-RIII) malaria.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0002-9637
pubmed:author
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
114-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10432067-Adolescent, pubmed-meshheading:10432067-Adult, pubmed-meshheading:10432067-Animals, pubmed-meshheading:10432067-Antimalarials, pubmed-meshheading:10432067-Blood, pubmed-meshheading:10432067-Child, pubmed-meshheading:10432067-Child, Preschool, pubmed-meshheading:10432067-Chloroquine, pubmed-meshheading:10432067-Drug Combinations, pubmed-meshheading:10432067-Drug Resistance, Multiple, pubmed-meshheading:10432067-Female, pubmed-meshheading:10432067-Humans, pubmed-meshheading:10432067-Infant, pubmed-meshheading:10432067-Malaria, Falciparum, pubmed-meshheading:10432067-Male, pubmed-meshheading:10432067-Mefloquine, pubmed-meshheading:10432067-Middle Aged, pubmed-meshheading:10432067-Nigeria, pubmed-meshheading:10432067-Plasmodium falciparum, pubmed-meshheading:10432067-Prospective Studies, pubmed-meshheading:10432067-Pyrimethamine, pubmed-meshheading:10432067-Random Allocation, pubmed-meshheading:10432067-Sulfadoxine
pubmed:year
1999
pubmed:articleTitle
Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum.
pubmed:affiliation
Department of Medicine, University of Calabar, Nigeria.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't